Not all patients with CLL involve therapy. In spite of all current advances, the iwCLL continue to recommends watchful observation for clients with asymptomatic illness.86 This recommendation is based on not less than two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).10